Fast Access Healthcare
Fast Access Healthcare was paid $3.62M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 48% of everything it billed.
33Billing provider infoFAST ACCESS HEALTHCARE
CHATTANOOGA, TN 37421
CHATTANOOGA, TN 37421
33aNPI1063619997assigned 07/03/2007
33bProvider typeRegistered Nurse
28Total paid$3.62M
24GClaims370,544
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Registered Nurse providers in Tennessee
Rank by total paid#2 of 79
Median peer was paid$5K
This provider vs. median724×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,953 | $745K | |
| 2019 | 35,323 | $572K | |
| 2020 | 45,557 | $470K | |
| 2021 | 71,237 | $581K | |
| 2022 | 62,522 | $533K | |
| 2023 | 58,420 | $457K | |
| 2024incomplete | 40,532 | $267K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 48% | 43,254 | 31,860 | $1.76M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 19% | 23,375 | 17,016 | $677K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.4% | 14,277 | 10,065 | $196K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.2% | 2,995 | 2,149 | $114K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 2.8% | 631 | 457 | $100K |
| 94010 | 1.9% | 4,449 | 3,332 | $70K | |
| 80305 | 1.7% | 11,518 | 9,028 | $63K | |
| 81025 | 1.7% | 14,504 | 11,095 | $61K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 784 | 612 | $48K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 1.3% | 1,013 | 819 | $47K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 1,380 | 1,158 | $40K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 450 | 399 | $39K |
71 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.0% | 654 | $38K |
| 81002 | <1% | 24,678 | $36K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,355 | $36K |
| 93000 | <1% | 3,398 | $34K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 287 | $30K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,897 | $30K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,603 | $22K |
| 81003 | <1% | 20,868 | $21K | |
| 99406 | <1% | 2,907 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,205 | $13K |
| 99497 | <1% | 596 | $10K | |
| 93922 | <1% | 429 | $10K | |
| 82947 | <1% | 5,195 | $10K | |
| E0570 | Nebulizer, with compressor | <1% | 582 | $7K |
| 1159F | <1% | 26,642 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 159 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,559 | $6K |
| 1160F | <1% | 26,517 | $6K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 168 | $4K |
| 93225 | <1% | 206 | $4K | |
| 96127 | <1% | 1,211 | $4K | |
| 69210 | <1% | 146 | $4K | |
| 3074F | <1% | 19,559 | $3K | |
| 36416 | <1% | 4,236 | $3K | |
| 96160 | <1% | 1,266 | $3K | |
| 3078F | <1% | 16,147 | $3K | |
| 3079F | <1% | 8,760 | $3K | |
| 3008F | <1% | 26,800 | $2K | |
| 1125F | <1% | 2,496 | $2K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,607 | $2K |
| 93925 | <1% | 31 | $2K | |
| 86308 | <1% | 683 | $2K | |
| 93227 | <1% | 127 | $2K | |
| 3077F | <1% | 3,107 | $2K | |
| 99441 | <1% | 128 | $2K | |
| 99350 | Prolong home eval add 15m | <1% | 105 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,956 | $2K |
| 1126F | <1% | 1,551 | $2K | |
| 95117 | <1% | 231 | $2K | |
| 93975 | <1% | 23 | $2K | |
| 76770 | <1% | 62 | $2K | |
| 82962 | <1% | 1,371 | $1K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 305 | $1K |
| 1170F | <1% | 3,116 | $1K | |
| A7005 | Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable | <1% | 251 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 61 | $1K |
| 3075F | <1% | 3,477 | $1K | |
| 3080F | <1% | 1,829 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 172 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,356 | $1K |
| 93978 | <1% | 12 | $973.84 | |
| 93970 | <1% | 15 | $936.37 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 46 | $821.49 |
| 93880 | <1% | 13 | $735.37 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 158 | $684.73 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 19 | $658.16 |
| 94664 | <1% | 81 | $532.21 | |
| 96161 | <1% | 139 | $354.86 | |
| 99051 | <1% | 279 | $322.06 | |
| 99349 | <1% | 82 | $162.24 | |
| 92551 | <1% | 22 | $119.55 | |
| 99386 | <1% | 148 | $116.46 | |
| G0245 | Initial physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) which must include: (1) the diagnosis of lops, (2) a patient history, (3) a physical examination that consists of at least the following elements: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of a protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear and (4) patient education | <1% | 19 | $47.70 |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 111 | $24.74 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 131 | $7.75 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 30 | $0.15 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 121 | $0.00 |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 0% | 185 | $0.00 |
| 99387 | 0% | 117 | $0.00 | |
| 99366 | 0% | 935 | $0.00 | |
| 3044F | 0% | 176 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKERLEY, JONATHAN (OWNER PHYSICIAN)